Biohope

Biohope, founded in 2015, is an emerging private biotechnology and ICT company that develops innovative diagnostic tools to personalize and optimize the clinical management of patients under immunosuppressive or modulating therapies.

Today, there are no methods to predict the response to immunosuppressive drugs or to personalize such treatments. To address this need, Biohope has developed and patented the Immunobiogram (IMBG), a revolutionary in vitro diagnostic tool that, combined with software and databases, allows the application of precision medicine in immunosuppressive treatments for patients with inflammatory or autoimmune disorders.

The IMBG test offers a response pattern (sensitivity vs. resistance) of each patient’s T cells to existing immunosuppressive drugs for a wide range of doses. The IMBG is initially being used in kidney transplant patients, of whom 50% would expect to lose the new organ in the first 10 years, mainly due to failure in immunosuppressive therapy. In the future, the IMBG is expected to be applied to other types of transplants and autoimmune diseases.

The IMBG has successfully completed international trials, resulting in high-impact publications, CE marking, and patents in the European Union and the USA. Biohope operates under the ISO 13485 standard and has a license for manufacturing and clinical laboratory.

Biohope aims to become a global reference in personalized medicine by offering innovative, practical, and top-tier solutions that significantly improve clinical outcomes related to autoimmune conditions. This benefits patients, doctors, and the entire healthcare system.

At Biohope, we are proud to share and follow our company’s principles:

• Ethical business practices and Corporate Social Responsibility;
• Courage and orientation towards achieving exceptional results;
• Promotion of innovation, adaptation to changes, and continuous learning;
• Open, honest, and frequent communication with all key stakeholders.